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Summary
Hemophilia A is an X-linked disease of coagulation caused by deficiency of factor VIII. Using cloned
cDNA and synthetic oligonucleotide probes, we have now screened 240 patients and found CG-to-TG
transitions in an exon in nine. We have previously reported four of these patients; and here we report the
remaining five, all of whom were severely affected. In one patient a TaqI site was lost in exon 23, and in
the other four it was lost in exon 24. The novel exon 23 mutation is a CG-to-TG substitution at the codon
for amino acid residue 2166, producing a nonsense codon in place of the normal codon for arginine. Simi-
larly, the exon 24 mutations are also generated by CG-to-TG transitions, either on the sense strand produc-
ing nonsense mutations or on the antisense strand producing missense mutations (Arg to Gln) at position
2228. The novel missense mutations are the first such mutations observed in association with severe hemo-
philia A. These results provide further evidence that recurrent mutations are not uncommon in hemophilia
A, and they also allow us to estimate that the extent of hypermutability of CG dinucleotides is 10-20
times greater than the average mutation rate for hemophilia A.
Introduction
Hemophilia A is one of the most common inherited
diseases of blood coagulation in man (McKee 1983).
It is inherited as an X-linked recessive, and one-third
of the cases are thought to represent de novo muta-
tions (Haldane 1935). The disease is caused by a
deficiency of coagulation factor VIII (FVIII), and clin-
ical severity is closely correlated with the plasma
concentration of FVIII. Nevertheless, considerable
heterogeneity exists among different families, and
-10% of patients develop specific antibodies against
FVIII, called FVIII inhibitors, that usually appear af-
ter therapy with FVIII concentrates (McKee 1983). In
general, patients with severe disease (i.e., FVIII levels
, 1 U/dl) are most prone to develop inhibitors.
Received August 11, 1987; revision received November 23,
1987.
Address for correspondence and reprints: Haig H. Kazazian, Jr.,
M.D., Genetics Unit, CMSC 10-110, The Johns Hopkins Hospital,
600 N. Wolfe Street, Baltimore, MD 21205.
© 1988 by The American Society of Human Genetics. All rights reserved.
0002-9297/88/4205-0007$02.00
The FVIII gene has been isolated, characterized,
and expressed in vitro (Gitschier et al. 1984; Toole et
al. 1984; Vehar et al. 1984; Wood et al. 1984). The
gene is 186 kb in length and contains 26 exons en-
coding a 9-kb mRNA and a protein of 2,351 amino
acids. The functional epitopes of the FVIII protein
molecule are largely unknown. Exon 14 encodes a
sequence of 925 amino acids called the B domain,
deletion of which does not appear to affect the in
vitro synthesis of FVIII (Toole et al. 1986).
The availability of cloned FVIII gene fragments has
made possible the study of molecular defects in pa-
tients with hemophilia A (Antonarakis et al. 1985;
Gitschier et al. 1985, 1986; Youssoufian et al. 1986,
1987). Because of the clinical heterogeneity of this
disease, the large size of the FVIII gene, the pool of
new mutations, and the loss of mutant alleles in the
population within successive generations, it has been
suggested that a large number of genetic lesions can
cause hemophilia A (Antonarakis et al. 1985; Git-
schier et al. 1985), to the extent that each afflicted
family may harbor its own distinct mutation. How-
ever, we have recently described spontaneous recur-
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Table I
Clinical Characteristics
FVIII Level FVIII Antigen Inhibitor Titer
Patient,a Age (Years) (U/dl) (U/dl) (BU/ml)
JH-14, 17 ..................... <1 <1 1.8-5.0
JH-15, 52 ..................... <1 <1 18.0-30.0
JH-16,40 ..................... <1 <1 0.0
JH-18, 34 ..................... <1 <1 0.0
JH-19, 28 ..................... <1 ... 0.0
a All Caucasian males.
rences of two different point mutations in severe
hemophilia A (Youssoufian et al. 1986). These muta-
tions generated nonsense codons in exons 18 and 22
of the FVIII gene by substitutions of T for C at CG
dinucleotides. The occurrence of these mutations at
CG dinucleotides was significant because these sites
are thought to be mutation hot spots in higher ani-
mals (Salser 1977; Mandel and Chambon 1979; Bird
1980; Nussinov 1981; Barker et al. 1984). The mech-
anism of this phenomenon appears to be methylation
of cytosine 5' to guanine and the subsequent spon-
taneous deamination of 5-methylcytosine to thymine
(Coulondre et al. 1978).
We now describe a novel nonsense mutation in
exon 23 of the FVIII gene and two different point
mutations in exon 24 (one nonsense and a novel mis-
sense), each of which apparently occurred indepen-
dently in two different families. All five mutations
affect CG dinucleotides and generate either TG or
CA when the substitutions occur on the coding
strand or noncoding strand, respectively. From the
proportion of mutations at CG dinucleotides in our
survey of 240 patients with hemophilia A, we esti-
mate the propensity of CG dinucleotides to undergo
mutations in the coding region of the FVIII gene.
Methods
Hematologic Studies
Of the 240 patients whose DNA was screened for
gene defects, 80% were classified as severe and 20%
were classified as mild to moderate. All five patients
whose defects are presented here had severe hemo-
philia A associated with FVIII levels <1 U/dl as mea-
sured by clotting assays and FVIII antigen levels
determined by an immunoradiometric assay (Lazar-
chick and Hoyer 1978) (table 1). All had received
extensive transfusions with FVIII concentrates and
cryoprecipitates. In addition, two patients (JH-14
and JH-15) had evidence of FVIII inhibitors as mea-
sured by the Bethesda method (Kasper et al. 1975). In
each family the mother of the proband was an obli-
gate carrier of hemophilia A.
Restriction-Endonuclease Analysis
Genomic DNA was isolated from peripheral blood
leukocytes by standard techniques (Antonarakis et
al. 1985). Five micrograms of DNA was digested to
completion with one of various restriction enzymes
under conditions recommended by the manufactur-
ers. Gel electrophoresis, transfer to nitrocellulose
filters, hybridization with nick-translated probes,
washing, and autoradiography were performed ac-
cording to procedures described elsewhere (An-
tonarakis et al. 1985; Youssoufian et al. 1986). The
following cloned FVIII cDNA fragments (provided
by Drs. J. Toole and J. Wozney of Genetics Institute,
Inc.) were used as probes: (a) probe A, a 1.7-kb KpnI
cDNA fragment that spans exons 1-12, and (b)
probe BC, a 6.5-kb EcoRI cDNA fragment that
spans exons 14-26 (Toole et al. 1984; Antonarakis
et al. 1985; Youssoufian et al. 1986).
DNA Polymorphism Analysis
The following polymorphic sites within and closely
linked to the FVIII gene were analyzed: (a) a BclI site
in intron 18 of the FVIII gene (Gitschier et al. 1985),
(b) an XbaI site in intron 22 of the FVIII gene (Wion
et al. 1986), (c) a BglI site in intron 25 of the FVIII
gene (Antonarakis et al. 1985), (d) a BglII site de-
tected with the anonymous probe DXS15 (Harper et
al. 1984), and (e) multiple TaqI site polymorphisms
detected with the anonymous DNA fragment DXS52
(Oberle et al. 1985). The latter two DNA fragments
map at the Xq27-q28 region and are closely linked to





Designation of Oligonucleotide Exon of FVIII Oligonucleotide Sequence
HEM 23 ........................ 23 Normal S'-TATTGCTCGATACATCCGT-3'
HEM 23m ....................... 23 Nonsense 5'-TATTGCTTGATACATCCGT-3'
HEM 24-C ...................... 24 Normal 5'-GCTCGACTTCACCTCCAAG-3'
HEM 24-T ...................... 24 Nonsense S'-GCTTGACTTCACCTCCAAG-3'
HEM 24-A ...................... 24 Missense 5'-GCTCAACTTCACCTCCAAG-3'
probes were provided by Drs. K. Davies and J. L.
Mandel, respectively, while the intron 22 probe was
provided by Dr. R. Lawn of Genentech, Inc.
Oligonucleotide Analysis
Nineteen-base-long oligonucleotides (table 2) were
chemically synthesized, end-labeled using T4-poly-
nucleotide kinase and y32P-ATP, further purified by
electrophoresis on a 20% polyacrylamide sequencing
gel, and extracted from this gel by a crush-soak
method (Wallace et al. 1981; Youssoufian et al.
1986). Hybridization to dried agarose gel was per-
formed at the calculated melting temperature (Tm)
minus 4 degrees C for :3 h, washed in 2 x SSPE/
0.1% SDS at 25 C, then washed further in 2 x SSPE
at 2 C below Tm for 2 min and subjected to auto-
radiography. The agarose gel was reused after re-
moval of the first probe by alkaline denaturation.
Results
Our screening strategy for FVIII mutations in-
volved restriction analysis with TaqI, SstI, and EcoRI
and successive hybridizations with probe A and
probe BC, as described elsewhere (Youssoufian et al.
1986, 1987). To date, we have analyzed the genomic
DNA of 240 unrelated, randomly obtained individ-
uals and families with hemophilia A. Some of these
families were unselectively obtained from clinic pop-
ulations, while others were referred for carrier de-
tection or prenatal diagnosis. We have previously
reported four point mutations involving TaqI restric-
tion sites from a subset of 83 patients of the 240
reported here (Antonarakis et al. 1985; Youssoufian
et al. 1986).
Family JH- 14
Digestion with TaqI and hybridization with probe
BC showed a new 3.8-kb fragment in the patient
from family JH-14 (fig. 1A, III-3; fig. 2A, 111-3) in
place of the normal 1.4-kb fragment (fig. 1A). This
result localized the absent TaqI site to exon 23 of the
FVIII gene (fig. 1 C; see Gitschier et al. 1985). The
patient's mother (fig. 2A, II-2) also showed this
change, whereas the sister, father, and maternal
grandmother (figs. 1 A, 2A; data for father not
shown) did not. Digestion of the patient's DNA with
other restriction enzymes or hybridization with probe















TaqI Tai TI TaqI
Figure I Restriction analysis of DNA cleaved with TaqI and
hybridized with probe BC. A, Family JH-14; B, families JH-15 and
JH-16; C, partial restriction map of FVIII DNA cleaved with TaqI.




















Figure 2 Analysis of the exon 23 mutation. A, Pedigree of
family JH-14: E, normal male; 0, normal female; *, hemophilic
male; and 0, carrier female. Letters below symbols indicate X-
chromosome haplotypes of polymorphic restriction sites. Hap-
lotypedesignations: A, + - + + 3; B. - - - - 2; C, + + +
+ 2. These symbols represent the DNA polymorphic sites in the
following order: BclI, XbaI, BgII, BgIII, and TaqI (see Methods).
Haplotype of I-1 is uncertain. Also shown are results of oligonu-
cleotide analysis of genomic DNA from members of family JH-14
that was digested with EcoRI and hybridized with (B) HEM 23
and (C) HEM 23m. See table 1 for sequence of oligonucleotides.
Long arrow indicates non-FVIII gene sequences.
detected with TaqI most likely represents a point mu-
tation.
On the basis of previous observations of TaqI site
mutations (Antonarakis et al. 1985; Gitschier et al.
1985, 1986; Youssoufian et al. 1986), we postulated
that this loss of a TaqI site is due to a CG-to-TG
transition. We synthesized two oligonucleotides, one
representing the normal sequence of exon 23 sur-
rounding the TaqI site and the other representing the
presumed mutant sequence that differs from the nor-
mal by the substitution of a T for a C in the TaqI site
(table 2). Digestion of genomic DNA with EcoRI
normally produces a 4.8-kb fragment that contains
exons 23-25 of the FVIII gene (Gitschier et al. 1984).
The normal oligonucleotide probe, HEM 23, does
not hybridize to this fragment from the affected male
(fig. 2B, III-3). However, the DNA from the hetero-
zygous mother, the normal grandmother, and the













Figure 3 Analysis of the exon 24 mutations. Oligonu-
cleotide analysis of genomic DNA from families JH-15, JH-16,
and JH-18 that was digested with SstI and hybridized with (A)
HEM 24-C, (B) HEM 24-T, and (C) HEM 24-A. Bro. = brother;
Mo. = mother; and Sis. = sister.
ment (fig. 2A, II-2, 1-2, and II-1, respectively). A con-
stant, non-FVIII fragment is seen in all individuals.
By contrast, the mutant probe, HEM 23m, hybridizes
specifically to the 4.8-kb fragment from the DNA of
the patient and his mother (fig. 2C, III-3 and 11-2,
respectively) but not to the DNA of other family
members or of a normal female control (fig. 3C).
Therefore, the change in the TaqI site of exon 23 is
substitution of a T for a C, which generates a non-
sense codon (TGA) in place of the normal arginine
codon (CGA) at position 2166 of the FVIII gene.
We attempted to determine the parental origin of
the new mutation in the patient's mother by perform-
ing DNA polymorphism analysis on various family
members. The analysis was incomplete because the
maternal grandfather was deceased (see fig. 2A). Af-
ter analyzing five different polymorphic sites within
and closely linked to the FVIII gene, it was evident
that the X-chromosome haplotype with which this
mutation is associated was also shared by the mater-
nal grandmother and uncle (fig. 2A, I-2 and II-3,
respectively). Therefore, although it is possible that
the mutation-bearing X chromosome was contrib-
uted by the maternal grandfather, who by chance
happened to have this same haplotype, it is more
likely that it arose de novo on an X chromosome
contributed by the maternal grandmother. It is
noteworthy that the ages of the maternal grandfather
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and grandmother were 49 and 33 years, respectively,
at the time of conception of their carrier daughter.
Families JH-IS, JH- 16, JH- 18, andJH- 19
A different TaqI site alteration was observed in
four other unrelated patients with hemophilia A.
When DNA from the patients of families JH-15, JH-
16, JH-18, or JH-19 was digested with TaqI and hy-
bridized with probe BC, a new 4.2-kb fragment was
found in place of a normal 1.4-kb fragment (fig. 1 B;
data for JH-18 and JH-19 not shown). The result
localized the altered TaqI site to exon 24 (fig. 1 C).
No other changes were noted with other combina-
tions of restriction enzymes and probes (data not
shown). Obligate carriers from each family also
showed this TaqI site change (data not shown). These
results were suggestive of a point mutation, possibly
a C-to-T transition at CG dinucleotide either on the
sense strand (CG-TG) or the antisense strand. The
latter mutation yields a CG-CA substitution on
the sense strand. The former mutation has been de-
scribed elsewhere in an inhibitor-positive patient
with severe hemophilia A (Gitschier et al. 1985). To
determine the precise nucleotide change, three oligo-
nucleotides that flank the exon 24 TaqI site but differ
from each other by the single substitution of either a
T for a C or an A for a G within the Taq I site (table
2) were synthesized. The normal oligonucleotide,
HEM 24-C, does not hybridize to the 8.3-kb frag-
ment of SstI-cleaved DNA from the patients of these
families (fig. 3A). With this probe three constant
non-FVIII sequences are observed in all individuals.
The oligonucleotide bearing the first mutant se-
quence, HEM 24-T, hybridizes specifically to the
8.3-kb SstI fragment from the affected males from
families JH-15 and JH-16, as well as to that of fe-
males from family JH-16 who are heterozygous for
this mutation (fig. 3B). Therefore, the exon 24 muta-
tion in these two patients is a C-to-T transition at
codon 2228, generating a nonsense codon in place of
arginine, and is identical to the exon 24 mutation
described elsewhere (Gitschier et al. 1985). On the
other hand, the oligonucleotide bearing the second
presumed mutant sequence, HEM-A, hybridizes to
the 8.3-kb SstI fragment from affected males in the
JH-18 and JH-19 families, as well as to that of carrier
females (fig. 3 C; data not shown for JH-19). Thus,
the mutation in the latter two families is a CG-to-CA
change at codon 2228, a mutation generating a
glutamine in place of arginine at this position in the
protein. No FVIII:C Ag could be demonstrated in
the plasma of any of these patients.
To demonstrate that these four mutations repre-
sent independent events, we analyzed intragenic poly-
morphic sites (BclI and BglI) and the two extragenic
sites that are closely linked to the FVIII gene (see
Methods). The affected X chromosome in JH-15 dif-
fered from that of JH-16 at the intragenic BclI site,
and the affected X chromosome in JH-18 differed
from that of JH-19 at both intragenic sites (data not
shown). These differences in intragenic polymorphic
sites, in conjunction with pedigree analysis showing
lack of relationship, constitute strong evidence for
independent origins of these four exon 24 mutations.
Discussion
In this study we have described a novel mutation in
exon 23 of the FVIII gene, two independent occur-
rences of a novel missense mutation in exon 24, and
two further independent occurrences of an exon 24
nonsense mutation described elsewhere (Gitschier et
al. 1985). All five of these mutations involve CG-to-
TG or CG-to-CA transitions.
Considerable evidence indicates that the missense
mutation described here is causally related to hemo-
philia A. This mutation in codon 2228 has not been
observed in more than 600 normal or hemophilic X
chromosomes (Antonarakis et al. 1987; S. E. An-
tonarakis, H. Youssoufian, and H. H. Kazazian, Jr.,
unpublished observations). The independent recur-
rence of this mutation in association with severe he-
mophilia A lends further credence to a causal role.
Moreover, since the arginine residue at position 2228
is conserved in both copies of the C domain (Git-
schier et al. 1984; Toole et al. 1984), the substitution
of a neutral amino acid, glutamine, for the positively
charged arginine could produce an important struc-
tural alteration in the FVIII protein.
It has become clear that CpG dinucleotides play a
prominent role in mutagenesis in higher animals
(Salser 1977; Mandel and Chambon 1979; Bird
1980; Nussinov 1981; Barker et al. 1984). Evidence
in support of this proposal includes the significant
underrepresentation of this dinucleotide in vertebrate
genomes (Nussinov 1981), a higher frequency of
polymorphism observed with restriction enzymes
(e.g., Taql or MspI) that contain CpG in their recog-
nition sequences (Barker et al. 1984), and recurrent
point mutations in exons 18 and 22 of the FVIII gene
(Youssoufian et al. 1986). Furthermore, mutations
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that involve CpG dinucleotides have been described
in ot1-antitrypsin (Kidd et al. 1983), adenosine
deaminase (Bonthron et al. 1985), insulin (Shibasaki
et al. 1985), antithrombin III (Duchange et al. 1986),
factor IX (Bentley et al. 1986), and protein C (Romeo
et al. 1987). Thus, C-to-T transitions at CpG dinu-
cleotides have been observed in a variety of heritable
disorders, although a systematic evaluation of their
relative importance as a cause of mutation has not
been available.
Within the coding region of the FVIII gene there
are five TaqI sites that can potentially yield nonsense
codons (Gitschier et al. 1984). Mutations at all five of
these sites have now been described (Antonarakis et
al. 1985; Gitschier et al. 1985, 1986; Youssoufian et
al. 1986; and present report), and all of them involve
C-to-T transitions. In addition, two G-to-A transi-
tions in exons 24 and 26 have also been associated
with hemophilia A (Gitschier et al. 1986; and present
report). Thus, for the 10 potential C-to-T transitions
at these five sites, seven mutations of this type have
now been observed. In our sample of 240 patients,
we have observed five of these seven mutations and
have characterized nine independent occurrences of
these five mutations.
Because a relatively large number of CG-to TG-or
CG-to-CA mutations have now been characterized in
the FVIII gene, it is possible to estimate the excess
contribution of C-to-T transitions leading to hemo-
philia A. This estimate requires an assessment of the
total number of different mutations that produce he-
mophilia A, a number that may be estimated as fol-
lows: (1) For nonsense mutations, examination of the
coding sequence of the FVIII gene (Gitschier et al.
1984) reveals that, following single nucleotide
changes, 793 codons can potentially yield nonsense
codons. (2) For frameshift mutations, by analogy
with the ,B-thalassemias (Kazazian and Antonarakis
1987), the number of frameshifts may be roughly
equal to the number of nonsense mutations. (3) For
missense mutations, a reasonable comparison can
again be made with known ,-chain variants. ,B-
Globin has 146 codons, and there are 110 r-chain
variants that produce a clinical phenotype (unstable
hemoglobin, abnormal oxygen affinity, hemoglobin
M, or sickling) in the heterozygous state (Bunn and
Forget 1986, p. 382), indicating that the frequency of
clinically recognizable missense mutations per codon
is -.75 for this gene. In the case of FVIII, the fre-
quency of deleterious missense mutations per codon
is likely to be somewhat smaller. Of the 2,351 amino
acids that make up the protein, at least 581 (derived
from the B domain) are thought to be dispensable for
in vitro synthesis and procoagulant activity (Toole et
al. 1986). Therefore, of the remaining 1,770 codons,
we estimate that approximately 1,300 missense
mutations may be clinically significant. (4) Tran-
scriptional and processing mutations include splice-
site mutations (three per nucleotide at the donor GT
and acceptor AG splice sites of each intron plus an
unknown number of mutations in consensus se-
quences at splice sites) and others that affect promo-
ter and other 5' elements, for a total of approxi-
mately 350. (5) Gene deletions from our own patient
population have a prevalence of 6% in this disease
(Youssoufian et al. 1987). Therefore, the sum total of
potential mutations to hemophilia A by this calcula-
tion is approximately 790 + 790 + 1,300 + 350 +
200 = 3,430. We believe that this estimate is quite
conservative. For example, it is possible that missense
mutations in the B domain may well have deleterious
effects; the inclusion of these potentially deleterious
mutations would further raise the total number of
mutations.
Since we have surveyed five sites that can yield
seven C-to-T transitions capable of producing hemo-
philia A, the expected frequency of C-to-T mutations
in these patients is 7/3,430. This figure is in contrast
to the observed frequency of 9/240 (or 3.75%), giv-
ing an increased relative mutation rate of CG to TG
or of CG to CA of approximately 18. Even if one
completely eliminates the most speculative number in
the calculation-i.e., that of missense mutations-
one gets an increased relative mutation rate of 10. A
reasonable range on this estimate of the increase in
relative mutation rate is 10-20.
It is postulated that one-third of the mutations in
X-linked lethal disorders are due to de novo events
(Haldane 1935). In the case of the exon 23 mutation,
the carrier mother most likely acquired this mutation
as a germ-line, de novo event. To date, at least 13 of
29 mutations characterized in our sample of 240 pa-
tients have occurred de novo within 2 generations
(Youssoufian et al. 1986, 1987; H. Youssoufian, S. E.
Antonarakis, and H. H. Kazazian, Jr., unpublished
data).
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